Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Tirzepatide contributed 48,649 more life-years gained per 100,000 people, and semaglutide generated 35,634 more life-years gained per 100,000 people than lifestyle intervention alone.

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Switching to tirzepatide also led to a weight loss of 10.5 kg (23.1 lb) compared with 3.6 kg (7.9 lb) with the higher dulaglutide dose (P<0.001), according to Liana Billings, MD, of the University ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was funded by Eli Lilly, the pharmaceutical company that manufactures ...

May 12, 2025 – Turns out, two really is better than one – at least when it comes to weight loss drugs. In the first head-to-head trial of its kind, people with obesity who took tirzepatide ...